Continuously Nebulized Albuterol in Severe Exacerbations of Asthma in Adults: A Case-Controlled Study

References

• Hillman K, Bishop G. Acute severe asthma. Pulmonary and Critical Care Medicine, R C Bone. CV Mosby, St. Louis 1994; 1–20
   Google Scholar
• Libretto S E. review of the toxicology of salbutamol. Arch Toxicol 1994; 68: 213–216
   PubMed Web of Science ®Google Scholar
• Moler F W, Hurwitz M E, Custer J R. Improvement in clinical asthma score and PaC02 in children with severe asthma treated with continuously nebulized terbutaline. J Allergy Clin Immunol 1988; 83: 1101–1109
   Google Scholar
• Amado M, Portnoy J. A comparison of low and high doses of continuously nebulized terbutaline for treatment of severe exacerbations of asthma. Ann Allergy 1988; 60: 165, abstract
   Google Scholar
• Portnoy J, Aggarwal J. Continuous terbutaline nebulization for the treatment of severe exacerbations of asthma in children. Ann Allergy 1988; 60: 368–371
   PubMedGoogle Scholar
• Reisman J, Galdes-Sebalt M, Kazim F. Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. J Allergy Clin Immunol 1988; 82: 16–20
   Google Scholar
• Ba M, Thivierge R L, Lapierre J G. Effects of continuous inhalation of salbutamol in acute asthma. Am Rei> Respir Dis 1987; 135: A326, abstract
   Google Scholar
• Robertson C F, Smith F, Beck R. Response to frequent low doses of nebulized salbutamol in acute asthma. J Pediatr 1985; 206: 672–674
   Google Scholar
• Schuh S, Parkin P, Rajan A. High- versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989; 83: 513–518
   PubMed Web of Science ®Google Scholar
• Kelly H W, McWilliams B C, Katz R. Safety of frequent high dose nebulized terbutaline in children with acute severe asthma. Ann Allergy 1990; 64: 229–233
   PubMedGoogle Scholar
• Singh M, Kumar L. Continuous nebulised salbutamol and oral once a day prednisone in status asthmaticus. Arch Dis Child 1993; 69: 416–419
   PubMedGoogle Scholar
• Papo M C, Frank J, Thompson A E. prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993; 22: 1479–1486
   Google Scholar
• Katz R W, Kelly H W, Crowley M R. Safety of continuous nebulized albuterol for bronchospasm in infants and children. Pediatrics 1993; 92: 666–669
   PubMed Web of Science ®Google Scholar
• Montgomery V L, Eid N S. Low-dose β-agonist continuous nebulization therapy for status asthmaticus in children. J Asthma 1994; 31: 201–207
   PubMed Web of Science ®Google Scholar
• Colacone A, Wolkove N, Stem E. Continuous nebulization of albuterol in acute asthma. Chest 1990; 97: 693–697
   PubMed Web of Science ®Google Scholar
• Olshaker J, Jerrard D, Barish R A. The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks. Am J Emerg Med 1993; 32: 131–133
   Google Scholar
• Lin R Y, Sauter D, Newman T. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Ann Emerg Med 1993; 22: 1847–1863
   PubMed Web of Science ®Google Scholar
• Rudnitsky G S, Eberlein R S, Schoffstall J M. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med 1993; 22: 1842–1846
   PubMedGoogle Scholar
• Lin R Y, Smith A J, Hergenroeder P. High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol. Chest 1993; 103: 221–225
   PubMed Web of Science ®Google Scholar
• Voss K R, Willsie-Ediger S K, Pyszczynski D R. Description of a delivery method for continuously aerosolized albuterol in status asthmaticus. J Asthma 1990; 27: 37–39
   PubMed Web of Science ®Google Scholar
• Knaus W A, Draper E A, Wagner D P. APACHE II; A severity of disease classification system. Crit Care Med 1985; 13: 818–829
   PubMed Web of Science ®Google Scholar
• Baker E, Willsie S, Marinac J. Continuously nebulized albuterol; A case controlled study. Am J Resprir Crit Care Med 1995; 151: A269
   PubMedGoogle Scholar
• Willsie S K, Salzman G, Oki J, Salamone J. Continuous vs intermittent nebulization of albuterol in status asthmaticus-A prospective study. Chest 1992; 102(2)91S
   PubMedGoogle Scholar
• American Medical Association Drug Evaluations Annual 1992, D R Bennett. American Medical Association, Chicago 1992; 475
   Google Scholar
• Roberts D E, Dobson K E, Hall K W. Effects of prolonged naloxone infusion in septic shock. Lancet 1988; 2: 699–702
   PubMedGoogle Scholar
• Driks M R, Craven D E, Celli B R. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. N Engl J Med 1987; 327: 1376–1382
   Google Scholar
• Kerver A J, Rommes J H, Mevissen-Verhage E A. Prevention of colonization and infection in critically ill patients: A prospective randomized study. Crit Care Med 1988; 16: 1087–1093
   PubMed Web of Science ®Google Scholar
• Day A C, Rank A PN, Judson J A. Grading asthma severity; Using the APS component of the APACHE II system. Intensive Care Med 1993; 19: 221–226
   PubMed Web of Science ®Google Scholar
• McFadden E R. Clinical physiologic correlates in asthma. J Allergy Clin Immunol 1986; 77: 1–5
   PubMedGoogle Scholar
• Papo V T, Werner P. Dose-related dilatation of airways after inhalation of metaproterenol sulfate. Chest 1976; 70: 205–211
   PubMedGoogle Scholar
• Nelson H S, Spector S L, Whitsett T L. The bron-chodilator response to inhalation of increasing doses of aerosolized albuterol. J Allergy Clin Immunol 1983; 72: 371–375
   PubMed Web of Science ®Google Scholar
• Kelly H W. New β2-adrenergic agonist aerosols. Clin Pharm 1985; 4: 393–403
   PubMedGoogle Scholar
• O'Connor B J, Aikman S L, Barnes P J. Tolerance to the nonbronchodilator effects of inhaled β2-agonists in asthma. N Engl J Med 1992; 327: 1204–1208
   PubMed Web of Science ®Google Scholar
• Taylor D R, Sears M R, Herbison G P. Regular inhaled P-agonists in asthma: Effects on exacerbation and lung function. Thorax 1993; 45: 134–138
   Google Scholar
• Georgopoulos D, Wong D, Anthonisen N R. Tolerance to β2-agonists in patients with chronic obstructive pulmonary disease. Chest 1990; 97: 280–284
   PubMed Web of Science ®Google Scholar